Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel versus docetaxel + radium-223 in metastatic castration-resistant prostate cancer
NL-OMON54758Phase 3Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, radium-223 dichloride and prednisone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall survival. Started Oct 2019; status: recruiting.
02
Drugs
docetaxelradium-223 dichlorideprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON54758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54758.